Научный путь члена-корреспондента РАН, профессора А. А. Фирсова

1. Соловьев В.Н., Фирсов А.А., Филов В.А. Фармакокинетика (руководство). Медицина, М.: 1980.

2. Фирсов А.А., Пиотровский В.К. Фармакокинетические методы в биофармации: оценка биодоступности и пресистемная элиминация лекарственных средств. Итоги науки и техники ВИНИТИ, Т. 14, ВИНИТИ, М.: 1984. — С. 113-223.

3. Фирсов А.А., Назаров А. Д., Черных В. М. Фармакокинетические подходы к оптимизации антибиотикотерапии. Итоги науки и техники ВИНИТИ. 1989. — Т. 17.

4. Firsov A. A., Savarino D, Ruble M., Gilbert D., Manzano B., Medeiros A. A., Zinner S. H. Predictors of effect of ampicillin-sulbactam against TEM-1 /3- lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother 1996; 40: 734-738.

5. Firsov A. A., Ruble M, Gilbert D., Savarino D., Manzano B., Medeiros A. A., Zinner S. H. Net effect of inoculum size on antimicrobial action of ampi- cillin-sulbactam: studies using an in vitro dynamic model. Antimicrob Agents Chemother 1997; 41: 7-12.

6. Firsov A. A., Mattie. Relationships between antimicrobial effect and area under the concentration-time curve as a basis for comparison of modes of antibiotic administration: meropenem bolus injections versus continuous infusions. Antimicrob Agents Chemother 1997; 41: 352-56.

7. Firsov A. A., Shevchenko A. A., Vostrov S. N., Zinner S. H. Inter- and intraquinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrob Agents Chemother 1998; 42: 659-665.

8. Firsov A. A., Vostrov S. N., Shevchenko A. A., Zinner S. H., Cornaglia G., Portnoy Y. A. MIC-based interspecies prediction ofthe antimicrobial effects of ciprofloxacin on bacteria of different susceptibilities in an in vitro dynamic model. Antimicrob Agents Chemother 1998; 42: 2848-2852.

9. Firsov A. A., Vostrov S. N., Shevchenko A. A., Portnoy Y. A., Zinner S. H. A new approach to in vitro comparisons of antibiotics in dynamic models: equivalent area under the curve /MIC breakpoints and equiefficient doses oftrovafloxacin and ciprofloxacin against bacteria of similar susceptibilities. Antimicrob Agents Chemother 1998; 42: 2841-2847.

10. Firsov A. A., Vostrov S. N., Kononenko O. V., Zinner S. H., Portnoy Y. A. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother 1999; 43: 498-502.

11. Firsov, A. A., Lubenko I. Y., Portnoy Y. A., Zinner S. H., Vostrov S. N. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: Gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother 2001; 45: 927-931.

12. Firsov A. A., Zinner S. H. Use of modeling techniques to aid in antibiotic selection. Curr Infect Dis Rep 2001; 3: 35-43.

13. Zinner, S. H., Firsov A. A., Gilbert, D. Simmons K., Lubenko I. Y. The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: Prediction of equiefficient doses. J Antimicrob Chemother 2001; 48: 821-826.

14. Firsov, A. A., Vostrov S. N., Lubenko I. Y., Drlica K., Portnoy Y. A., Zinner S. H. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47: 1604-1613.

15. Zinner S. H., Lubenko I. Y., Gilbert D., Simmons K., Zhao X., Drlica K., Firsov A. A. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing. J Antimicrob Chemother 2003; 52: 616-622.

16. Firsov A. A., Zinner S. H., Lubenko I. Y. In vitro dynamic models as tools to predict antibiotic pharmacodynamics. In: Nightingale C. H., Ambrose P. G., Drusano G. L., Murakawa T.; editors. Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 2nd ed. New York: Informa Healthcare USA, Inc.; 2007; 45-78.

17. Firsov A. A., Portnoy Y.A., Zinner S. H. PK/PD-based prediction of «antimutant» antibiotic exposures using in vitro dynamic models. In: Fong I.W., Shlaes D., Drlica K.; Editors. Antimicrobial Resistance in the 21st Century. 2nd ed. Springer International Publishing; 2018; 643-666.

18. Проведение качественных исследований биоэквивалентности лекарственных средств. Методические указания. Под ред. В.Г.Кукеса, В.П.Жердева, А.К.Стародубцева. М.: 2004.

19. Фирсов А.А., Жердев В.П., Портной Ю.А., Колыванов Г.Б., Литвин А.А., Барманова Е.Ю. Методические рекомендации по проведению доклинических исследований фармакокинетики лекарственных средств. Под ред. А.Н.Миронова. Руководство по проведению доклинических исследований лекарственных средств. М.: Гриф и К, 2012. — Т. 1. — С. 845-855